Screening for the Key Proteins Associated with Rete Testis Invasion in Clinical Stage I Seminoma via Label-Free Quantitative Mass Spectrometry

• Published in: Cancers Vol. 13; no. 21; p. 5573
• Main Authors: Borszéková Pulzová, Lucia Borszéková, Roška, Jan, Kalman, Michal, Kliment, Ján, Slávik, Pavol, Smolková, Božena, Goffa, Eduard, Jurkovičová, Dana, Kulcsár, Ľudovít, Lešková, Katarína, Bujdák, Peter, Mego, Michal, Bhide, Mangesh R., Plank, Lukáš, Chovanec, Miroslav
• Format: Journal Article
• Language: English
• Published: Basel MDPI AG 08.11.2021; MDPI
• Subjects: Basal ganglia; Biomarkers; Biopsy; Cancer therapies; Carboplatin; Central nervous system diseases; Chemotherapy; Decision making; Ezrin; Gene expression; Mass spectrometry; Mass spectroscopy; Medical prognosis; Metastasis; Movement disorders; Multivariate analysis; Nitrogen; PARK7 protein; Patients; Peptides; Proteins; Proteomes; Risk factors; Scientific imaging; Seminoma; Software; Surveillance; Tumors; Vimentin; Vinculin; United States > US
• ISSN: 2072-6694; 2072-6694
• DOI: 10.3390/cancers13215573

Rete testis invasion (RTI) is an unfavourable prognostic factor for the risk of relapse in clinical stage I (CS I) seminoma patients. Notably, no evidence of difference in the proteome of RTI-positive vs. -negative CS I seminomas has been reported yet. Here, a quantitative proteomic approach was used to investigate RTI-associated proteins. 64 proteins were differentially expressed in RTI-positive compared to -negative CS I seminomas. Of them, 14-3-3γ, ezrin, filamin A, Parkinsonism-associated deglycase 7 (PARK7), vimentin and vinculin, were validated in CS I seminoma patient cohort. As shown by multivariate analysis controlling for clinical confounders, PARK7 and filamin A expression lowered the risk of RTI, while 14-3-3γ expression increased it. Therefore, we suggest that in real clinical biopsy specimens, the expression level of these proteins may reflect prognosis in CS I seminoma patients.